The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Spleen tyrosine kinase (SYK) is the best known for its involvement in immune receptor signalling, mediated by binding of SYK tandem Src‐homology 2 domains to tandem phosphotyrosine in immunoreceptor tyrosine‐based activation motifs (ITAMs). ITAM adaptors or ITAM‐containing receptor tails mediate signalling from B‐ and T‐cell receptors, Fc receptors and many C‐type lectins, including dectin‐1. Recent data point to constitutive binding of SYK to the cytoplasmic domain of toll‐like receptor‐4 (TLR4). This SYK‐TLR4 binding increases upon TLR4 dimerization and phosphorylation, and SYK plays a prominent role in TLR4 signalling in response to LPS in neutrophils and monocytes. SYK also plays an important role in TLR4‐mediated macrophage responses to minimally oxidized low‐density lipoprotein (mmLDL), which is a form of oxidized LDL relevant to development of human atherosclerosis. Interestingly, mmLDL‐induced effects in macrophages, which occur via TLR4, are predominantly MyD88 independent. This unmasks the role of the SYK branch of TLR4 signalling, which mediates modest cytokine release via activation of AP‐1 transcription and robust reactive oxygen species generation and cytoskeletal rearrangements. The latter results in extensive membrane ruffling and macropinocytosis, leading to lipoprotein uptake and foam cell formation, a hallmark of atherosclerotic lesions. Because inhibitors of SYK activity, such as fostamatinib, are in advanced clinical trials for rheumatoid arthritis and other autoimmune diseases, understanding the role of SYK in signalling via TLR4 is of immediate importance. This signalling pathway seems to be particularly important in TLR4 activation by host‐derived, damage‐associated molecular pattern ligands, such as mmLDL, relevant to development of atherosclerosis and other chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513 · cited 2×
“Another possible explanation is that TLR4 is never a stand-alone receptor responding to bacterial or endogenous challenge, but rather part of a receptor cluster – each component of the cluster influences the ultimate signalling pattern (Schmitz and Orso, 2002; Stewart et al., 2010; Triantafilou and Triantafilou, 2010).”
BackgroundSignaling in innate immunity and inflammation
Newton, K., & Dixit, V. M. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006049 · Cited by 1,513 · cited 1×
“The detailed description of the signalling intermediates in the TLR4/MyD88 pathway can be found in recent reviews (Newton and Dixit, 2012).”
BackgroundThe SYK tyrosine kinase: A crucial player in diverse biological functions
Mócsai, A., Ruland, J., & Tybulewicz, V. L. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2765 · Cited by 1,368 · cited 8×
“This interaction is proposed to coordinate integrin signalling cascades with co-opted ITAM-containing transmembrane adaptors (Mocsai et al., 2010).”
BackgroundInfluentialMichelsen, K. S., Wong, M. H., Shah, P. K., Zhang, W., Yano, J., Doherty, T. M., Akira, S., Rajavashisth, T. B., & Arditi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403249101 · Cited by 1,019 · cited 2×
“A deficiency in TLR4 or MyD88 attenuates the development of atherosclerosis in hyperlipidemic Apoe-/- mice, likely owing to the reduction in macrophage recruitment to atherosclerotic lesions (Bjorkbacka et al., 2004; Michelsen et al., 2004).”
BackgroundCD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4
Zanoni, I., Ostuni, R., Marek, L. R., Barresi, S., Barbalat, R., Barton, G. M., Granucci, F., & Kagan, J. C. (2011) · Cell · doi:10.1016/j.cell.2011.09.051 · Cited by 997
Sutterwala, F. S., Ogura, Y., Szczepanik, M., Lara-Tejero, M., Lichtenberger, G. S., Grant, E. P., Bertin, J., Coyle, A. J., Galán, J. E., Askenase, P. W., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.02.004 · Cited by 980 · cited 1×
“For example, eritoran (E5564), a lipid A analogue, binds to MD-2 and inhibits LPS activation of TLR4 (Rossignol and Lynn, 2005), and resatorvid (TAK-242) targets Cys747 in the intracellular domain of TLR4 and inhibits its signalling (Ii et al., 2006; Takashima et al., 2009).”
BackgroundThe S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase
Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya, M., Akira, S., Aburatani, H., & Maru, Y. (2008) · Nature Cell Biology · doi:10.1038/ncb1794 · Cited by 642 · cited 2×
“, 2009); serum amyloid A3 secreted by premetastatic tumours (Hiratsuka et al., 2008); and minimally oxidized low-density lipoprotein (mmLDL), but not native LDL (Miller et al.”
BackgroundBjörkbacka, H., Kunjathoor, V. V., Moore, K. J., Koehn, S., Ordija, C. M., Lee, M. A., Means, T., Halmen, K., Luster, A. D., Golenbock, D. T., et al. (2004) · Nature Medicine · doi:10.1038/nm1008 · Cited by 634 · cited 2×
“A deficiency in TLR4 or MyD88 attenuates the development of atherosclerosis in hyperlipidemic Apoe-/- mice, likely owing to the reduction in macrophage recruitment to atherosclerotic lesions (Bjorkbacka et al., 2004; Michelsen et al., 2004).”
BackgroundDisruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E–deficient mice
Cyrus, T., Witztum, J. L., Rader, D. J., Tangirala, R., Fazio, S., Linton, M. F., & Funk, C. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5897 · Cited by 523 · cited 2×
“…(Alox15) oxidizes LDL in vivo and that Alox15-/- mice on the Ldlr-/- or Apoe-/- background fed with a high-fat diet develop less atherosclerosis than Alox15 wild-type mice (Cyrus et al., 1999; 2001; George et al., 2001; Huo et al., 2004; Zhao et al., 2005; Poeckel et al., 2009; Rong et al., 2012).”
BackgroundInterplay between obesity and associated metabolic disorders: New insights into the gut microbiota
Cani, P. D., & Delzenne, N. M. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.016 · Cited by 377 · cited 1×
“Furthermore, many obese and diabetic patients have the so-called metabolic endotoxemia (Amar et al., 2008; Erridge, 2008; Cani and Delzenne, 2009; Laugerette et al., 2011).”
BackgroundSyk-coupled C-type lectins in immunity
Kerrigan, A. M., & Brown, G. D. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.01.002 · Cited by 170
Cited by
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
How the immune system shapes atherosclerosis: roles of innate and adaptive immunity
Roy, P., Orecchioni, M., & Ley, K. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00584-1 · Cited by 565
The Immunomodulatory Effects of Statins on Macrophages
Sheridan, A., Wheeler-Jones, C. P. D., & Gage, M. C. (2022) · Immuno · doi:10.3390/immuno2020021 · Cited by 48
Wang, W.-H., Krisenko, M. O., Higgins, R. L., Morman, R. E., & Geahlen, R. L. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1800084 · Cited by 3
Metadata
- Authors
- Miller, Y. I., Choi, S., Wiesner, P., & Bae, Y. S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-10-08
- Volume
- 167
- Issue
- 5
- Pages
- 990-999
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2101935191
- Cited by
- 164
- References
- 11
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.